albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
==== 2500–2599 ==== Trade Union Reform and Employment Rights Act 1993 (Commencement No. 2 and Transitional Provisions) Order 1993 (S.I. 1993/2503) Combined Probation Areas (Dorset) Order 1993 (S.I. 1993/2512) Teachers' (Superannuation and Compensation for Premature Retirement) (Scotland) Amendment Regulations 1993 (S.I. 1993/2513) Coal Industry Act 1992 (Commencement) Order 1993 (S.I. 1993/2514) Export of Goods (Control) (Amendment No. 5) Order 1993 (S.I. 1993/2515) Friendly Societies (Qualifications of Actuaries No.2) Regulations 1993 (S.I. 1993/2518) Friendly Societies (Amendment) Regulations 1993 (S.I. 1993/2519) Friendly Societies (Insurance Business No. 2) Regulations 1993 (S.I. 1993/2520) Friendly Societies (Authorisation No. 2) Regulations 1993 (S.I. 1993/2521) A11 Trunk Road (Roudham Heath to Attleborough Improvement and Slip Roads) Order 1993 (S.I. 1993/2524) A11 Trunk Road (Roudham Heath to Attleborough Improvement) (Detrunking) Order 1993 (S.I. 1993/2525) Protection of Wrecks (Designation No. 2) Order 1993 (S.I. 1993/2526) Police (Amendment) (No. 4) Regulations 1993 (S.I. 1993/2527) Police Cadets (Amendment) Regulations 1993 (S.I. 1993/2528) Fodder Plant Seeds (Amendment) Regulations 1993 (S.I. 1993/2529) Seeds (Registration, Licensing and Enforcement) (Amendment) Regulations 1993 (S.I. 1993/2530) Local Government Superannuation (Maternity Absence) Regulations 1993 (S.I. 1993/2531) Sea Fisheries Districts (Variation) Order 1993 (S.I. 1993/2532) Suppression of Terrorism Act 1978 (Application of Provisions) (India) Order 1993 (S.I.
== Habitat and distribution == Amanita virosa is found in woodland in late summer and autumn, especially in association with beech and chestnut, but also with pine, spruce, and fir. As with most Amanita species, it forms a mutually beneficial, ectomycorrhizal relationship with the roots of these trees. Amanita virosa was originally described from Sweden and is known throughout Europe, with additional confirmed records from northern Asia (China). The name was formerly used for similar-looking agarics in North America, but research has shown that these American species, including the eastern Amanita bisporigera, the western A. ocreata, and the northern Amanita amerivirosa, are distinct.
=== Plants === Plant genomes encode hundreds of proteases, largely of unknown function. Those with known function are largely involved in developmental regulation. Plant proteases also play a role in regulation of photosynthesis.
Sources: en.wikipedia.org
==== 1952–53 ==== When he joined the Cardinals, broadcaster Harry Caray started calling him "Vinegar Bend," and the nickname stuck. He was hailed as "the left-handed Dizzy Dean" by sportswriter Red Smith, which Mizell called "a perty heavy load for a boy to tote." Added to St. Louis's starting rotation for the 1952 campaign, Mizell made his major league debut on April 22 against the Cincinnati Reds. He gave up two runs in the first inning, then held the Reds scoreless for the rest of the game, though he took the loss in a 2–1 defeat. Two starts later, on May 2, he limited the Philadelphia Phillies to four hits and two runs in a complete game, winning in the ninth when Peanuts Lowrey broke a 2–2 tie with an RBI-single. After that win, he lost three games in a row, then received four consecutive no decisions. He ended the winless streak on June 21, when he struck out 11 in his first major league shutout against the Boston Braves. That started a streak of six decisions won in a row, during which time Mizell posted a 3.05 ERA. He would not lose again until August 27. On September 5, he threw his second shutout of the year, tying his season high with 11 strikeouts in a 4–0 victory over the Pittsburgh Pirates. Mizell finished his rookie season with a 10–8 record and a 3.65 ERA in 30 starts. He led the National League (NL) in strikeouts per 9 innings pitched with a 6.9 mark, and his 146 strikeouts ranked fourth in the league (behind Warren Spahn's 183, Bob Rush's 157, and Robin Roberts's 148). However, he also led the league in walks (103, tied with Herm Wehmeier).
=== Acceptance === Individuals with dwarfism often face prejudice and stereotypes. Research by Klein (2019) has demonstrated that awareness of the stigmatization of this group can promote full participation in society. The research by Green and Pinter (2018) in the field of humor and social psychology can provide insights to reduce stereotypes and promote a more objective perception.
In Situ NMR: In situ NMR enables real-time observation of chemical and structural changes in batteries while they are operating. This is particularly important for studying transient species that only exist under working conditions, such as certain intermediate reaction products. In situ NMR has become a critical tool for understanding processes like lithium and sodium plating and dendrite formation during battery cycling. Ex Situ NMR: Ex situ NMR is used after the battery has been disassembled, allowing for high-resolution analysis of battery components. It is often employed to study a wide range of nuclei, including 1H, 2H, 6Li, 7Li, 13C, 15N, 17O, 19F, 25Mg, 29Si, 31P, 51V, 133Cs. Many of these nuclei are quadrupolar or present in low abundance, making them difficult to detect. However, ex situ NMR benefits from better sensitivity and narrower linewidths, which can be further improved by employing larger sample volumes, higher magnetic fields, or magic angle spinning (MAS).
Sources: en.wikipedia.org
Pulp degeneration Increasing age Orthodontic treatment Traumatic occlusion Dental caries Pulp stones usually consist of circular layers of mineralised tissues. These layers are made up of blood clots, dead cells and collagen fibres. Occasionally, pulp stones appear surrounded by odontoblast-like cells that contain tubules. Pulp stones can reach as high as 50% in surveyed samples. Pulp stones are estimated to typically range from 8–9%. Pulpal calcifications are more common in females and more frequent in maxillary teeth compared to mandibular teeth. The reason is uncertain. They are more common in molar teeth, especially first molars compared to second molars and premolars. A review suggested this was because the first molars are the first teeth to be located in the mandible (lower jaw) and have longer exposure to degenerative changes. They also have a larger blood supply. In general, pulp stones do not require treatment. Depending on the stones' size and location, they may interfere with endodontic treatment and should be removed.
Hepcidin is a regulator of iron metabolism. It inhibits iron transport by binding to the iron export channel ferroportin which is located in the basolateral plasma membrane of gut enterocytes and the plasma membrane of reticuloendothelial cells (macrophages), ultimately resulting in ferroportin breakdown in lysosomes. It has been shown that hepcidin is able to bind to the central cavity of ferroportin, thus occluding iron export from the cell. This suggests that hepcidin is able to regulate iron export independently of ferroportin endocytosis and ubiquitination, and is thus quickly inducible and reversible. In enterocytes, this prevents iron transmission into the hepatic portal system, thereby reducing dietary iron absorption. In macrophages, ferroportin inhibition causes iron be to stored within the cell. Increased hepcidin activity is partially responsible for reduced iron availability seen in anemia of chronic inflammation, such as kidney failure; this may explain why patients with end stage kidney failure may not respond to oral iron replacement. Any one of several mutations in hepcidin will result in juvenile hemochromatosis. The majority of juvenile hemochromatosis cases are caused by mutations in hemojuvelin. Mutations in TMPRSS6 can cause anemia through dysregulation of hepcidin. Hepcidin has strong antimicrobial activity against Escherichia coli strain ML35P and Neisseria cinerea and weaker antimicrobial activity against Staphylococcus epidermidis, Staphylococcus aureus and Streptococcus agalactiae.
=== Purification === The biotin tag can be used in affinity chromatography together with a column that has avidin (or streptavidin or neutravidin) bound to it, which is the natural ligand for biotin. However, harsh conditions (e.g., 6M GuHCl at pH 1.5) are needed to break the avidin/streptavidin - biotin interaction, which will most likely denature the protein carrying the biotin tag. If isolation of the tagged protein is needed, it is better to tag the protein with iminobiotin. This biotin analogue gives strong binding to avidin/streptavidin at alkaline pH, but the affinity is reduced upon lowering the pH. Therefore, an iminobiotin-tagged functional protein can be released from an avidin/streptavidin column by decreasing the pH (to around pH 4).
=== 28 December === The Department of Foreign Affairs and Trade confirmed the death of Sage O’Donnell, the fourth Australian to die fighting for Ukraine. The Russian health ministry announced that it will permit Russian soldiers who had been fighting in Ukraine to have their sperm frozen in cryobanks for free. The Chief of the Main Intelligence Directorate of Ukraine, Kyrylo Budanov said that neither Ukraine nor Russian forces were able to advance.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.